Pacific Biosciences Of California (PACB) FCF Margin (2010 - 2026)

Pacific Biosciences Of California's FCF Margin history runs 17 years deep, the most recent figure standing at 128.39% for Q1 2026.

• On a quarterly basis, FCF Margin fell 607.0% year-over-year to 128.39% in Q1 2026; TTM through Mar 2026 was 72.62%, a 4430.0% increase from a year earlier, with the FY2025 full-year figure at 71.2%, up 6661.0% from the prior year.
• FCF Margin eased to 128.39% in Q1 2026 per PACB's latest filing, from 44.64% in the prior quarter.
• Across five years, FCF Margin topped out at 44.64% in Q4 2025 and bottomed at 252.99% in Q1 2023.
• The 5-year median for FCF Margin is 122.32% (2025), against an average of 142.22%.
• Across the five-year window, FCF Margin plunged 16814 bps in 2022 and jumped 13725 bps in 2023, its largest moves.
• Year by year, FCF Margin stood at 239.35% in 2022, then surged by 57 bps to 102.1% in 2023, then increased by 19 bps to 82.26% in 2024, then jumped by 46 bps to 44.64% in 2025, then tumbled by 188 bps to 128.39% in 2026.
• Per Business Quant, the three latest PACB FCF Margin figures stand at 128.39% (Q1 2026), 44.64% (Q4 2025), and 48.44% (Q3 2025).